Xinbao Pill ameliorates heart failure via regulating the SGLT1/AMPK/PPARα axis to improve myocardial fatty acid energy metabolism

• Published in: Chinese medicine Vol. 19; no. 1; pp. 82 - 19
• Main Authors: Pan, Linjie, Xu, Zhanchi, Wen, Min, Li, Minghui, Lyu, Dongxin, Xiao, Haiming, Li, Zhuoming, Xiao, Junhui, Cheng, Yuanyuan, Huang, Heqing
• Format: Journal Article
• Language: English
• Published: England BioMed Central 11.06.2024; BMC
• Subjects: AMPK/PPARα axis; Antibodies; Cardiomyocytes; Congestive heart failure; Disease; Drug dosages; Echocardiography; Energy; Energy metabolism; Experiments; Fatty acids; FDA approval; Fenofibrate; Fibrosis; Heart failure; Hypertrophy; Isoproterenol; Laboratory animals; Metabolism; Myocardial energy metabolism; Neonates; Nuclear transport; Oxidation; Phosphorylation; SGLT1; Traditional Chinese medicine; Xinbao Pill; United States > US; China; Heart failure; Xinbao Pill; AMPK/PPARα axis; Myocardial energy metabolism; SGLT1

Heart failure (HF) is characterized by a disorder of cardiomyocyte energy metabolism. Xinbao Pill (XBW), a traditional Chinese medicine formulation integrating "Liushen Pill" and "Shenfu Decoction," has been approved by China Food and Drug Administration for the treatment of HF f...